QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - NYSE:QGEN - NL0015002CX3 - Common Stock
45.86 USD
+0.13 (+0.28%)
Taking everything into account, QGEN scores 6 out of 10 in our fundamental rating. QGEN was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making QGEN a very profitable company, without any liquidiy or solvency issues. QGEN has a decent growth rate and is not valued too expensively. This makes QGEN very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year QGEN was profitable.
In the past year QGEN had a positive cash flow from operations.
In the past 5 years QGEN has always been profitable.
QGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
QGEN's Return On Assets of 6.41% is amongst the best of the industry. QGEN outperforms 82.14% of its industry peers.
QGEN has a better Return On Equity (10.65%) than 80.36% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.66%, QGEN belongs to the top of the industry, outperforming 83.93% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 14.79%.
The 3 year average ROIC (7.25%) for QGEN is below the current ROIC(8.66%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROIC | 8.66% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
The Profit Margin of QGEN (18.30%) is better than 91.07% of its industry peers.
In the last couple of years the Profit Margin of QGEN has declined.
QGEN has a better Operating Margin (26.86%) than 94.64% of its industry peers.
In the last couple of years the Operating Margin of QGEN has grown nicely.
QGEN's Gross Margin of 64.18% is amongst the best of the industry. QGEN outperforms 85.71% of its industry peers.
In the last couple of years the Gross Margin of QGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so QGEN is still creating some value.
The number of shares outstanding for QGEN has been reduced compared to 1 year ago.
The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
The debt/assets ratio for QGEN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.97 indicates that QGEN is not in any danger for bankruptcy at the moment.
QGEN has a better Altman-Z score (3.97) than 78.57% of its industry peers.
QGEN has a debt to FCF ratio of 2.91. This is a good value and a sign of high solvency as QGEN would need 2.91 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.91, QGEN belongs to the best of the industry, outperforming 80.36% of the companies in the same industry.
A Debt/Equity ratio of 0.25 indicates that QGEN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.25, QGEN perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Altman-Z | 3.97 |
ROIC/WACC1.1
WACC7.84%
2.3 Liquidity
QGEN has a Current Ratio of 1.61. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.61, QGEN is not doing good in the industry: 69.64% of the companies in the same industry are doing better.
A Quick Ratio of 1.35 indicates that QGEN should not have too much problems paying its short term obligations.
The Quick ratio of QGEN (1.35) is worse than 69.64% of its industry peers.
The current and quick ratio evaluation for QGEN is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.20%, which is quite good.
The Earnings Per Share has been growing by 8.40% on average over the past years. This is quite good.
QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.15%.
Measured over the past years, QGEN shows a small growth in Revenue. The Revenue has been growing by 5.32% on average per year.
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
3.2 Future
QGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.02% yearly.
The Revenue is expected to grow by 7.38% on average over the next years.
EPS Next Y7.88%
EPS Next 2Y8.09%
EPS Next 3Y8.68%
EPS Next 5Y8.02%
Revenue Next Year5.25%
Revenue Next 2Y5.47%
Revenue Next 3Y5.89%
Revenue Next 5Y7.38%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.51, which indicates a rather expensive current valuation of QGEN.
Based on the Price/Earnings ratio, QGEN is valued cheaper than 85.71% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.41, QGEN is valued a bit cheaper.
The Price/Forward Earnings ratio is 17.66, which indicates a rather expensive current valuation of QGEN.
85.71% of the companies in the same industry are more expensive than QGEN, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.87, QGEN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.51 | ||
| Fwd PE | 17.66 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaply inside the industry as 91.07% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 83.93% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.05 | ||
| EV/EBITDA | 13.82 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
QGEN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.48
PEG (5Y)2.32
EPS Next 2Y8.09%
EPS Next 3Y8.68%
5. Dividend
5.1 Amount
With a yearly dividend of 0.55%, QGEN is not a good candidate for dividend investing.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.54. QGEN pays more dividend than 91.07% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.38, QGEN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
5.2 History
QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y8.09%
EPS Next 3Y8.68%
NYSE:QGEN (9/23/2025, 9:49:58 AM)
45.86
+0.13 (+0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.24%
Inst Owner Change-22.15%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap9.94B
Analysts75
Price Target52.82 (15.18%)
Short Float %3.15%
Short Ratio4.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.7%
Min EPS beat(2)-2.4%
Max EPS beat(2)7.8%
EPS beat(4)2
Avg EPS beat(4)1.23%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.51%
EPS beat(12)8
Avg EPS beat(12)3.69%
EPS beat(16)12
Avg EPS beat(16)5.44%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.16%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.61%
Revenue beat(12)3
Avg Revenue beat(12)-0.41%
Revenue beat(16)7
Avg Revenue beat(16)0.85%
PT rev (1m)2.48%
PT rev (3m)4.48%
EPS NQ rev (1m)0.43%
EPS NQ rev (3m)0.96%
EPS NY rev (1m)0%
EPS NY rev (3m)0.53%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)1.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.51 | ||
| Fwd PE | 17.66 | ||
| P/S | 4.87 | ||
| P/FCF | 20.05 | ||
| P/OCF | 14.73 | ||
| P/B | 2.84 | ||
| P/tB | 15.56 | ||
| EV/EBITDA | 13.82 |
EPS(TTM)2.35
EY5.12%
EPS(NY)2.6
Fwd EY5.66%
FCF(TTM)2.29
FCFY4.99%
OCF(TTM)3.11
OCFY6.79%
SpS9.41
BVpS16.17
TBVpS2.95
PEG (NY)2.48
PEG (5Y)2.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROCE | 11.67% | ||
| ROIC | 8.66% | ||
| ROICexc | 10.87% | ||
| ROICexgc | 46.44% | ||
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% | ||
| FCFM | 24.31% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexcg growth 3Y-31.24%
ROICexcg growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 94.78% | ||
| Cap/Sales | 8.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.61% | ||
| Profit Quality | 132.83% | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 3.97 |
F-Score8
WACC7.84%
ROIC/WACC1.1
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
EPS Next Y7.88%
EPS Next 2Y8.09%
EPS Next 3Y8.68%
EPS Next 5Y8.02%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
Revenue Next Year5.25%
Revenue Next 2Y5.47%
Revenue Next 3Y5.89%
Revenue Next 5Y7.38%
EBIT growth 1Y21.82%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.21%
EBIT Next 3Y22.62%
EBIT Next 5Y14.77%
FCF growth 1Y31.74%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y29.99%
OCF growth 3Y1.77%
OCF growth 5Y15.28%